Botanix Investor Centre

Botanix is an ASX-listed company (ASX:BOT), in a prime position for growth and to return value for shareholders. With deep expertise in dermatology and pharmaceutical product commercialisation, we are on track to disrupt some of the most lucrative global healthcare markets.

ASX: BOT | Share price


Change

Feb 4, 2021
April 6, 2017

Share Registry

Our share and options registers are maintained by Automic Group (Automic).

Security holders who wish to update personal or contact information, elect to receive communications electronically, such as the company’s annual report or notice of meeting, or provide banking details can do so via the Automic website here and follow the prompts, or contact Automic (using the details below).

When updating information electronically or contacting Automic you will need your Security Reference Number (SRN) or your Holder Identification Number (HIN) and your postcode. Both numbers are on your Issuer Sponsored/CHESS statements.

The share registry’s contact details are:

w: investor.automic.com.au
p: 1300 288 664 (within Australia) +61 (0)2 9698 5414 (Overseas)
e: hello@automicgroup.com.au

12 July 2022
December 9, 2019
September 17, 2019
January 31, 2019
November 15, 2018
August 13, 2018
April 9, 2018
November 13, 2017

Latest video

Botanix to Present at Euroz Hartleys Institutional Conference

Botanix Pharmaceuticals (ASX:BOT) announced that Botanix CEO…

Euroz Hartleys Healthcare Forum Presentation

Botanix Pharmaceuticals (ASX:BOT) announced that Botanix CEO,…

Botanix resubmission of NDA for Sofdra™ accepted

Botanix Pharmaceuticals has today announced the Company’s…

Botanix resubmission of NDA for Sofdra™ completed

Botanix Pharmaceuticals has announced that the Company has successfully…

FDA confirms approach to Sofdra™ NDA resubmission

Botanix Pharmaceuticals has announced that the Company has received…

$13.5M institutional placement

Botanix has today announced it has received firm commitments…

Research note | Continued Strong Sales from Japanese Partner

Euroz Hartleys has published a research note on the performance…

Check out our latest investor presentation

Sign up to receive our latest news

Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
ErrorHere